drugset
drugset / Trial / NCT05075460

Tucidinostat, Azacitidine Combined With CHOP Versus CHOP in Patients With Untreated Peripheral T-cell Lymphoma

NCT05075460 ↗

Phase 3 Unknown 107 enrolled Peking Union Medical College Hospital
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This is a prospective, multicenter, phase III study of Tucidinostat, Azacitidine combined with CHOP versus CHOP in patients with untreated peripheral T-cell lymphoma

Timeline

Start
2021-10-01
Primary completion
2024-05-30
Completion
2024-10-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Azacitidine Other / unclassified 200 mg Subcutaneous
Subject Tucidinostat Small molecule 20 mg Oral
Background Cyclophosphamide Other / unclassified 750 mg/m2 Intravenous
Background Epirubicin Small molecule 70 mg/m2 Intravenous
Background Prednisone Other / unclassified 100 mg Oral
Background Vinoresin Unknown 4 mg Intravenous

Indications

T-cell non-Hodgkin lymphoma